Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Korábbi kezelés

• Those who are currently undergoing clinical trials of other drugs;

Más betegség

• Active, known or suspected autoimmune disease;
• Known history of primary immunodeficiency;
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
• Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc., requiring emergency surgery;
• Uncontrolled intercurrent illness including but not limited to:
• People living with HIV (HIV antibody positive)
• Severe infections that are active or poorly clinically controlled
• Patients with active hepatitis
• Evidence of severe or uncontrolled systemic disease (e.g., severe psychiatric, neurological, epilepsy or dementia, unstable or incompensable respiratory, cardiovascular, hepatic or renal disease, uncontrolled hypertension [i.e., greater than or equal to CTCAE grade 2 hypertension despite medication]).

Laborértékek

• Patients with active bleeding or new thrombotic disease, taking therapeutic dose of anticoagulant drugs or bleeding tendency, abnormal coagulation function (INR\>1.5×ULN, APTT\>1.5×ULN);

Egyéb

• Pregnant or lactating female patients;
• Other patients who are considered by the investigator to be unsuitable for inclusion.

• -Patient's age: 18 years old - 80 years old -
• Rectal cancer patients diagnosed with adenocarcinoma by pathological examination of primary biopsy
• Patients with no prior treatment, preoperative clinical stage: cT3-4N+M0 rectal cancer patients (AJCC 8th);
• Patients who agree to undergo radical surgical treatment and have no contraindications to surgery as judged by the surgeon;
• No other multiple primary cancers;
• At least 1 measurable or evaluable lesion according to the efficacy evaluation criteria for solid tumors version 1.1 (RECIST v1.1);
• Expected survival time≥ 3 months;
• A score of 0-1 based on the United States Eastern Cooperative Oncology Group Performance Status Score (ECOG PS score);
• The investigator plans to give PD-1 monoclonal antibody combined with chemotherapy treatment regimen after evaluation, and signs informed consent.